Effect of chitosan‐alginate nanoparticles and ultrasound on the efficiency of gene transfection of human cancer cells

Background

Gene therapy has been used to treat a variety of health problems, but transfection inefficiency and the lack of safe vectors have limited clinical progress. Fabrication of a vector that is safe and has high transfection efficiency is crucial for the development of successful gene therapy. The present study aimed to synthesize chitosan‐alginate nanoparticles that can be used as carriers of the pAcGFP1‐C1 plasmid and to use these nanoparticles with an ultrasound protocol to achieve high efficiency gene transfection.

Methods

Chitosan was complexed with alginate and the pAcGFP1‐C1 plasmid at different charge ratios to create chitosan‐alginate‐DNA nanoparticles (CADNs). The average particle size and loading efficiency were measured. Plasmid DNA retardation and integrity were analysed on 1% agarose gels. The effect of CADNs and ultrasound on the efficiency of transfection of cells and subcutaneous tumors was evaluated.

Results

In the CADNs, the average size of incorporated plasmid DNA was 600–650 nm and the loading efficiency was greater than 90%. On the basis of the results of the plasmid DNA protection test, CADNs could protect the transgene from DNase I degradation. The transgene product expression could be enhanced efficiently if cells or tumor tissues were first given CADNs and then treated with ultrasound.

Conclusions

The use of CADNs combined with an ultrasound regimen is a promising method for safe and effective gene therapy. Copyright © 2009 John Wiley & Sons, Ltd.

     

Canstatin基因转染对人肝癌HepG-2细胞体外血管生成拟态的影响

目的:探讨转染Canstatin基因对人肝癌HepG-2细胞体外形成血管生成拟态的影响。方法:将Canstatin基因通过脂质体法转染人肝癌HepG-2细胞,行G418筛选获得转基因细胞克隆。用SDS-PAGE电泳检测Canstatin蛋白在转基因细胞培养上清液中的表达;建立HepG-2细胞人工基底膜基质凝胶体外三维细胞培养模型,观察HepG-2细胞能否形成血管生成拟态,并比较转基因和未转基因细胞的管道形成能力。结果:Canstatin在转染人HepG-2细胞中表达并分泌至上清液中,人肝癌HepG-2细胞在体外三维培养条件下能够形成血管生成拟态。Canstatin基因转染HepG-2细胞组的管状结构数量高于空载体组和HepG-2细胞组,转染细胞管道形成能力明显受抑制。结论:人肝癌HepG-2细胞株可形成血管生成拟态,Canstatin能抑制人肝癌细胞株HepG-2体外血管生成拟态形成。     

Surface adsorption of protein corona controls the cell internalization mechanism of DC-Chol-DOPE/DNA lipoplexes in serum

Serum has often been reported as a barrier to efficient lipid-mediated transfection. Here we found that the transfection efficiency of DC-Chol-DOPE/DNA lipoplexes increases in serum. To provide insight into the mechanism of lipoplex-serum interaction, several state-of-the-art methodologies have been applied. The nanostructure of DC-Chol-DOPE/DNA lipoplexes was found to be serum-resistant as revealed by high resolution synchrotron small angle X-ray scattering, while dynamic light scattering measurements showed a marked size increase of complexes. The structural stability of DC-Chol-DOPE/DNA lipoplexes was confirmed by electrophoresis on agarose gel demonstrating that plasmid DNA remained well protected by lipids. Proteomics experiments showed that serum proteins competed for the cationic surface of lipid membranes leading to the formation of a rich a ‘protein corona’. Combining structural results with proteomics findings, we suggest that such a protein corona can promote large aggregation of intact lipoplexes. According to a recently proposed size-dependent mechanism of lipoplex entry within cells, protein corona-induced formation of large aggregates most likely results in a switch from a clathrin-dependent to caveolae-mediated entry pathway into the cells which is likely to be responsible for the observed transfection efficiency boost. As a consequence, we suggest that surface adsorption of protein corona can have a high biological impact on serum-resistant cationic formulations for in vitro and in vivo lipid-mediated gene delivery applications.     

Gene delivery by cationic lipid vectors: overcoming cellular barriers

Non-viral vectors such as cationic lipids are capable of delivering nucleic acids, including genes, siRNA or antisense RNA into cells, thus potentially resulting in their functional expression. These vectors are considered as an attractive alternative for virus-based delivery systems, which may suffer from immunological and mutational hazards. However, the efficiency of cationic-mediated gene delivery, although often sufficient for cell biological purposes, runs seriously short from a therapeutics point of view, as realizing this objective requires a higher level of transfection than attained thus far. To develop strategies for improvement, there is not so much a need for novel delivery systems. Rather, better insight is needed into the mechanism of delivery, including lipoplex–cell surface interaction, route of internalization and concomitant escape of DNA/RNA into the cytosol, and transport into the nucleus. Current work indicates that a major obstacle involves the relative inefficient destabilization of membrane-bounded compartments in which lipoplexes reside after their internalization by the cell. Such an activity requires the capacity of lipoplexes of undergoing polymorphic transitions such as a membrane destabilizing hexagonal phase, while cellular components may aid in this process. A consequence of the latter notion is that for development of a novel generation of delivery devices, entry pathways have to be triggered by specific targeting to select delivery into intracellular compartments which are most susceptible to lipoplex-induced destabilization, thereby allowing the most efficient release of DNA, a minimal requirement for optimizing non-viral vector-mediated transfection. Dedicated to Prof. K. Arnold on the occasion of his 65th birthday.     

Cancer immunotherapy, mathematical modeling and optimal control

Clinical immunologists, among other problems, routinely face a question: what is the best time and dose for a certain therapeutic agent to be administered to the patient in order to decrease/eradicate the pathological condition? In cancer immunotherapies the therapeutic agent is something able to elicit an immune response against cancer. The immune response has its own dynamics that depends on the immunogenicity of the therapeutic agent and on the duration of the immune response. The question then is "how can we decide when and how much of the drug to inject so to have a prolonged and effective immune response to the cancer?". This question can be addressed in mathematical terms in two stages: first one construct a mathematical model describing the cancer-immune interaction and secondly one applies the theory of optimal control to determine when and to which extent to stimulate the immune system by means of an immunotherapeutic agent administered in discrete variable doses within the therapeutic period. The solution of this mathematical problem is described and discussed in this article. We show that the method employed can be applied to find the optimal protocol in a variety of clinical problems where the kinetics of the drug or treatment and its influence on the physiologic/pathologic functions have been described by a system of ordinary differential equations.     

PEI在动物皮肤组织基因转化中的应用研究

用低分子量的聚乙亚胺(PEI)开发一种新的非病毒基因转染系统,为基因在皮肤组织中的有效转染提供一种可靠、廉价的方法。将带有绿色荧光蛋白报告基因(gfp)的真核表达质粒与阳离子聚合物聚乙亚胺结合,用肝癌细胞株CM7721试验,研究其转染效率及可能引起的细胞毒性;进一步转染小鼠皮肤组织,研究转染基因的表达位置及持续表达时间。结果发现,低分子量PEI介导的细胞转染效率最高可达55%,转染效率与PEI结构无关(P>0·05),但是随着PEI分子量的增加,其转染活性略有下降。同时,随着分子量的增加,PEI对细胞的毒性也相应加大;小鼠皮肤转染实验显示,转染24h后,gfp即可在皮肤组织的毛囊、汗腺、皮脂腺等处高效表达,表达可持续7~9d;进一步对皮肤用氮酮、维甲酸处理后,gfp可在皮肤组织的颗粒层细胞中高效表达。PEI是一种高效、有用的非病毒基因转染载体,能够在体外培养的动物细胞及动物皮肤组织中进行基因转移,这对皮肤疾病的基因治疗具有潜在的应用价值。     

用于哺乳动物细胞转染的高纯度质粒DNA的制备

目的：建立简便高效、成本低廉和安全无污染的高纯度质粒提取方法。方法：在乙酸铵方法的基础上加以改进,主要改进之处在于增加了用聚乙二醇纯化质粒的步骤,并对溶液Ⅱ和溶液Ⅲ的成分和具体实验参数也做了合理的改进,以最少的步骤,充分去除了残存杂质,保证了质粒的超纯状态。结果：用本方法提取的质粒与用QIAGEN plasmid midi Kit提取的质粒在理化指标上没有差别,对哺乳动物胞具有同样的转染效率。结论：本方法可完全取代QIAGEN公司的试剂盒用于提取超纯质粒。     

一种可降解的阳离子聚合物基因转染试剂

目的：合成一种高效、低毒的新型阳离子聚合物载体。方法：以低分子量的聚乙烯亚胺（PEI）为阳离子聚合物的基本单位,以可水解的2,4-戊二醇二丙烯酸盐（PODOA）为交联剂,合成高分子聚合物。用DNA凝胶迟滞实验验证聚合物与DNA的亲和力,以绿色荧光蛋白基因和萤光素酶检测其基因转染效率,用聚合物凝胶电泳实验鉴定其降解性,以MTT法检测其细胞毒性。结果：聚合物具有高的DNA结合亲和力、高基因转染效率,基因转染后的萤光素酶活性高达3×10^9RLU／mg,其基因转染效率相当于甚至优于目前市售的转染试剂,而细胞毒性明显低于其他试剂。该聚合物在中性环境下可降解,而在酸性条件下非常稳定。结论：合成的聚合物具有高转染效率和低细胞毒性,可能在转染和基因治疗研究中起重要作用。